Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Neurology (clinical),Oncology
Link
http://academic.oup.com/neuro-oncology/article-pdf/20/1/113/23375830/nox144.pdf
Reference61 articles.
1. Randomized phase III controlled trials of therapy in malignant glioma: where are we after 40 years?;Br J Neurosurg,2008
2. Impact of cancer research bureaucracy on innovation, costs, and patient care;J Clin Oncol,2014
3. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer;J Natl Cancer Inst,2012
4. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials;North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials;J Clin Oncol,2006
5. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma;N Engl J Med,2014
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol;PLOS ONE;2024-07-26
2. Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice;eBioMedicine;2024-07
3. Proteasome inhibition for glioblastoma: Lessons learned and new opportunities;Neuro-Oncology;2024-06-27
4. Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma;Current Neurology and Neuroscience Reports;2024-04-05
5. Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas;Briefings in Bioinformatics;2024-03-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3